Veracyte Partners with Helix to Enhance Cancer Diagnostics and Patient Care

Advancing Cancer Diagnostics: Helix and Veracyte's Collaborative Initiative

Helix, a front-runner in precision health, partners with Veracyte, a distinguished player in cancer diagnostics, to enhance patient care for individuals diagnosed with high-risk localized and metastatic prostate cancer. This collaboration marks a significant development in the realm of cancer diagnostics, as it integrates Helix's comprehensive germline testing alongside Veracyte's Decipher® Prostate test. By combining these advanced diagnostic tools, urologists gain access to a broader spectrum of information regarding a patient’s cancer biology and inherited risk factors. This partnership aligns with the National Comprehensive Cancer Network® (NCCN®) guidelines, which advocate for germline genetic testing to inform treatment decisions, particularly the use of targeted therapies such as PARP inhibitors that can significantly alter patient outcomes.

The importance of this initiative lies in its potential to transform the standard of care in oncology. Helix CEO Dr. James Lu highlights the need for seamless access to genomic insights for cancer patients, extending beyond those treated in specialized centers. By incorporating both germline and transcriptomic information into a unified workflow, healthcare providers can make more informed decisions that are consistent with the latest clinical recommendations. This approach not only aids in determining appropriate treatment options but also helps identify risks for other cancers and provides essential information to family members who may also be affected.

This collaboration signifies a crucial step towards democratizing precision medicine. By leveraging Helix’s Exome+® assay and the Sequence Once, Query Often® model, the partnership aims to deliver high-quality genomic insights in a more streamlined and efficient manner, potentially reducing the necessity for repeat testing. Furthermore, when integrated with pharmacogenomic testing, the initiative allows healthcare providers to customize treatments based on individual genetic profiles, enhancing patient outcomes and paving the way for more personalized care in oncology.

In addition to this groundbreaking partnership, Helix’s ongoing commitment to advancing precision oncology is supported by the Helix Research Network®, the largest and rapidly expanding precision clinical research network globally. This platform has already initiated universal cancer screening programs, reinforcing Helix's mission to make genomic insights accessible to all cancer patients.

For further details on Helix's advancements in precision oncology and their collaborative work with Veracyte, interested parties are encouraged to visit Helix's official website.